Valuation: ProPhase Labs, Inc.

Market Cap 6L 5L 5L 5L 9L 5.83Cr 9L 58.22L 22.85L 2.92Cr 23.05L 22.54L 9.67Cr P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 91.42L 79.18L 73.81L 67.88L 1.28Cr 87Cr 1.3Cr 8.67Cr 3.4Cr 43Cr 3.43Cr 3.36Cr 144.04Cr EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-13.79%
1 week+108.33%
Current month+199.27%
1 month+60.26%
3 months-15.82%
6 months-10.71%
Current year-72.07%
1 week 0.03
Extreme 0.0326
0.14
1 month 0.03
Extreme 0.0326
0.14
Current year 0.03
Extreme 0.0326
0.47
1 year 0.03
Extreme 0.0326
6.66
3 years 0.03
Extreme 0.0326
74.8
5 years 0.03
Extreme 0.0326
152.5
10 years 0.03
Extreme 0.0326
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap.
09/09/25 Free

Chief Executive Officer

5,00,000 1.2036%
17/02/25 Free

Chief Operating Officer

5,00,000 1.6737%
14/02/25 Free

Director

1,00,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-13.79%+108.33%-95.94%-99.83% 6L
-0.21%+8.19%+95.99%+438.26% 3.93TCr
+0.52%+2.22%+19.16%+45.87% 2.54TCr
-0.40%-1.47%-20.62%-34.89% 775.54Cr
-3.12%+5.82%+20.92%+101.99% 527.32Cr
+0.95%+1.25%+18.56%+60.24% 331.55Cr
-1.40%+9.77%-34.45%+879.13% 208.49Cr
-3.44%+3.01%+179.89%-1.19% 202.09Cr
+0.54%+1.39%-9.53%-59.36% 190.76Cr
+7.57%+17.63%+22.29%-14.98% 178.77Cr
Average -1.29%+5.44%+19.63%+131.52% 888.75Cr
Weighted average by Cap. -0.08%+5.43%+51.61%+231.33%

Financials

2024 2025
Net sales 67.7L 58.63L 54.66L 50.27L 94.9L 64Cr 95.96L 6.42Cr 2.52Cr 32Cr 2.54Cr 2.49Cr 106.67Cr 43.45L 37.63L 35.08L 32.26L 60.91L 41Cr 61.59L 4.12Cr 1.62Cr 21Cr 1.63Cr 1.6Cr 68Cr
Net income -5.34Cr -4.62Cr -4.31Cr -3.96Cr -7.48Cr -507.42Cr -7.56Cr -51Cr -20Cr -253.89Cr -20Cr -20Cr -840.86Cr -1.47Cr -1.28Cr -1.19Cr -1.09Cr -2.07Cr -140.19Cr -2.09Cr -14Cr -5.49Cr -70Cr -5.54Cr -5.42Cr -232.31Cr
Net Debt 2.39Cr 2.07Cr 1.93Cr 1.77Cr 3.35Cr 227.21Cr 3.39Cr 23Cr 8.9Cr 113.68Cr 8.97Cr 8.78Cr 376.51Cr 85.28L 73.86L 68.85L 63.33L 1.2Cr 81Cr 1.21Cr 8.09Cr 3.18Cr 41Cr 3.2Cr 3.13Cr 134.38Cr
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
05/26/05 $0.0438 -8.79% 1,32,081
04/26/04 $0.0480 +15.80% 18,898
03/26/03 $0.0415 -0.76% 20,473
31/26/31 $0.0418 -16.46% 2,18,908
30/26/30 $0.0500 -16.67% 1,59,558

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock